Your Location:
Home >
Browse articles >
Sanren Decoction Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease by Protecting Mitochondrial Function
Original Article | Updated:2026-02-14
    • Sanren Decoction Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease by Protecting Mitochondrial Function

    • Chinese Journal of Integrative Medicine   Vol. 32, Issue 3, Pages: 223-231(2026)
    • DOI:10.1007/s11655-025-3845-6    

      CLC:
    • Accepted:06 June 2025

      Online First:27 October 2025

      Published:2026-03

    Scan QR Code

  • YIN Yi-xiao, HU Yi-yang, WANG Jing-jing, et al. Sanren Decoction Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease by Protecting Mitochondrial Function[J]. Chinese Journal of Integrative Medicine, 2026, 32(3): 223-231. DOI: 10.1007/s11655-025-3845-6.

  •  
  •  
icon
The trial reading is over, you can activate your VIP account to continue reading.
Deactivate >
icon
The trial reading is over. You can log in to your account, go to the personal center, purchase VIP membership, and read the full text.
Already a VIP member?
Log in >

0

Views

0

Downloads

0

CSCD

Alert me when the article has been cited
Submit
Tools
Download
Export Citation
Share
Add to favorites
Add to my album

Related Articles

Polysaccharide of Danggui Buxue Decoction Attenuates Colorectal Cancer via Modulating Intestinal Microflora and Metabolites
Effectiveness and Safety of Auricular Acupressure Combined with Periocular Thumbtack Needle Therapy for Premyopic Children: A Multicenter, Randomized, Controlled Trial
Huanglian Jiedu Decoction Alleviates Metabolic-Associated Fatty Liver Disease in vivo and in vitro via IRE1α/XBP1s Signaling Pathway
Efficacy and Safety of Qiming Granule for Nerve Injury Associated with Non-proliferative Diabetic Retinopathy: A Multicenter, Randomized, Non-inferiority, Active-Controlled Clinical Trial
Efficacy and Safety of Aurantii Fructus Immaturus Flavonoid Tablets in Patients with Functional Dyspepsia: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ⅲ Clinical Trial

Related Author

GUO Min
ZHANG Xin-chi
GUO Dong-fei
WEI Sai-xue
CAO Jian-nan
LI Xiao-dong
LIU De-wen
HOU Xin-yue

Related Institution

Laboratory of Chinese Medicine, Gansu Provincial Hospital of Traditional Chinese Medicine
Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.
EACHY Biopharmaceuticals Co., Ltd.
College of Pharmacy, Gansu University of Chinese Medicine
Experimental Research Center, China Academy of Chinese Medical Sciences
0